Robert Stratta to Immunosuppressive Agents
This is a "connection" page, showing publications Robert Stratta has written about Immunosuppressive Agents.
Connection Strength
3.627
-
Stratta RJ. The search for the optimal antibody induction strategy in kidney transplantation: still "hazy" after all these years. Clin Transplant. 2015 Jul; 29(7):569-72.
Score: 0.472
-
Stratta RJ, Rogers J, Orlando G, Farooq U, Al-Shraideh Y, Doares W, Kaczmorski S, Farney AC. Depleting antibody induction in simultaneous pancreas-kidney transplantation: a prospective single-center comparison of alemtuzumab versus rabbit anti-thymocyte globulin. Expert Opin Biol Ther. 2014 Dec; 14(12):1723-30.
Score: 0.452
-
Stratta RJ, Farney AC, Rogers J, Orlando G. Immunosuppression for pancreas transplantation with an emphasis on antibody induction strategies: review and perspective. Expert Rev Clin Immunol. 2014 Jan; 10(1):117-32.
Score: 0.432
-
Farney AC, Doares W, Rogers J, Singh R, Hartmann E, Hart L, Ashcraft E, Reeves-Daniels A, Gautreaux M, Iskandar SS, Moore P, Adams PL, Stratta RJ. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation. 2009 Sep 27; 88(6):810-9.
Score: 0.321
-
Singh RP, Stratta RJ. Advances in immunosuppression for pancreas transplantation. Curr Opin Organ Transplant. 2008 Feb; 13(1):79-84.
Score: 0.287
-
Farney A, Sundberg A, Moore P, Hartmann E, Rogers J, Doares W, Jarrett A, Adams P, Stratta R. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. Clin Transplant. 2008 Jan-Feb; 22(1):41-9.
Score: 0.285
-
Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients. Clin Transplant. 2004; 18 Suppl 12:61-6.
Score: 0.216
-
Stratta RJ, Alloway RR, Lo A, Hodge E. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. Transplantation. 2003 Apr 27; 75(8):1260-6.
Score: 0.206
-
Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Lo A, Kizilisik AT, Nezakatgoo N, Gaber LW, Gaber AO. Long-term experience with simultaneous kidney-pancreas transplantation with portal-enteric drainage and tacrolimus/mycophenolate mofetil-based immunosuppression. Clin Transplant. 2003; 17 Suppl 9:69-77.
Score: 0.201
-
Stratta RJ, Alloway RR, Hodge E, Lo A. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis. Clin Transplant. 2002 Feb; 16(1):60-8.
Score: 0.189
-
Kaczmorski S, Doares W, Winfrey S, Al-Geizawi S, Farney A, Rogers J, Stratta R. Gout and transplantation: new treatment option-same old drug interaction. Transplantation. 2011 Aug 15; 92(3):e13-4.
Score: 0.092
-
Farney AC, Doares W, Kaczmorski S, Rogers J, Stratta RJ. Cost-effective immunosuppressive options for solid organ transplantation: a guide to lower cost for the renal transplant recipient in the USA. Immunotherapy. 2010 Nov; 2(6):879-88.
Score: 0.087
-
Stratta RJ, Sundberg AK, Rohr MS, Farney AC, Hartmann EL, Roskopf JA, Iskandar SS, Hairston G, Kiger DF, Gautreaux MD, Anderson TK, Adams PL. Optimal use of older donors and recipients in kidney transplantation. Surgery. 2006 Mar; 139(3):324-33.
Score: 0.063
-
Winsett RP, Arheart K, Stratta RJ, Alloway R, Wicks MN, Gaber AO, Hathaway DK. Evaluation of an immunosuppressant side effect instrument. Prog Transplant. 2004 Sep; 14(3):210-6, 240.
Score: 0.057
-
Stratta RJ, Rohr MS, Sundberg AK, Armstrong G, Hairston G, Hartmann E, Farney AC, Roskopf J, Iskandar SS, Adams PL. Increased kidney transplantation utilizing expanded criteria deceased organ donors with results comparable to standard criteria donor transplant. Ann Surg. 2004 May; 239(5):688-95; discussion 695-7.
Score: 0.055
-
Stratta RJ, Rohr MS, Adams PL, Sundberg AK, Hartmann EL, Armstrong G, Anderson TK, Farney AC, Roskopf JA, Hairston G, Kiger DF, Nagaraj SK, Iskandar SS, Assimos DG. Kidney and pancreas transplantation at Wake Forest University Baptist Medical Center. Clin Transpl. 2003; 229-45.
Score: 0.050
-
Trofe J, Stratta RJ, Egidi MF, Lo A, Gaber LW, Shokouh-Amiri MH, Grewal HP, Honaker M, Hardinger K, Alloway RR, Gaber AO. Thymoglobulin for induction or rejection therapy in pancreas allograft recipients: a single centre experience. Clin Transplant. 2002; 16 Suppl 7:34-44.
Score: 0.047
-
Mori Ubaldini F, Stratta RJ, Nunez M. Delayed spontaneous hepatitis C virus elimination in a renal transplant patient following graft rejection. Transpl Infect Dis. 2019 Jun; 21(3):e13079.
Score: 0.039
-
Gruessner RW, Burke GW, Stratta R, Sollinger H, Benedetti E, Marsh C, Stock P, Boudreaux JP, Martin M, Drangstveit MB, Sutherland DE, Gruessner A. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation. 1996 Jan 27; 61(2):261-73.
Score: 0.031
-
Orlando G, Hematti P, Stratta RJ, Burke GW, Di Cocco P, Cocco PD, Pisani F, Soker S, Wood K. Clinical operational tolerance after renal transplantation: current status and future challenges. Ann Surg. 2010 Dec; 252(6):915-28.
Score: 0.022
-
Hartmann EL, Gatesman M, Roskopf-Somerville J, Stratta R, Farney A, Sundberg A. Management of leukopenia in kidney and pancreas transplant recipients. Clin Transplant. 2008 Nov-Dec; 22(6):822-8.
Score: 0.019
-
Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J, et al. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. Transplant Proc. 1993 Feb; 25(1 Pt 1):641-3.
Score: 0.006